**DEFINITIONS**

**** For purposes of this policy the following definitions are used:

  * Surveillance (Protocol) - patient is asymptomatic; no clinical signs or symptoms of organ injury/rejection.
  * For-Cause - patient has clinical signs or symptoms of organ injury/rejection.
  * AR - Acute Rejection
  * ACR - Acute Cellular Rejection
  * AMR - Antibody-Mediated Rejection
  * AV - Analytical Validity
  * CV - Clinical Validity
  * OPTN - Organ Procurement and Transplantation Network
  * GEP - Gene Expression Profiling
  * dd cfDNA - Donor-Derived Cell-Free DNA

This Medicare contractor will provide limited coverage for molecular
diagnostic tests used in the evaluation and management of patients who have
undergone solid organ transplantation. These tests can inform decision making
along with standard clinical assessments in their evaluation of organ injury
for active rejection (AR). **These tests may be ordered by qualified
physicians considering the diagnosis of AR, helping to rule in or out this
condition when assessing the need for or results of a diagnostic biopsy.**
They should be considered along with other clinical evaluations and results
and may be particularly useful in patients with significant contraindications
to invasive procedures.

Molecular diagnostic tests that assess a transplanted allograft for rejection
status are covered when ALL of the following criteria are met:

  * The test must provide information about at least one of the two following clinical status determinations: 
    * AR status
    * Cellular or Antibody-mediated rejection (ACR or AMR) status
  * The intended use of the test must be to inform clinical decision making as per the following: 
    * To assist in the evaluation of adequacy of immunosuppression, wherein a non-invasive or minimally invasive test can be used in lieu of a tissue biopsy in a patient for whom information from a tissue biopsy would be used to make a management decision regarding immunosuppression, OR
    * As a rule-out test for AR in validated populations of patients with clinical suspicion of rejection with a non-invasive or minimally invasive test to make a clinical decision regarding obtaining a biopsy, OR
    * For further evaluation of allograft status for the probability of allograft rejection after a physician-assessed pretest, OR
    * To assess rejection status in patients that have received a biopsy, but the biopsy results are inconclusive or limited by insufficient material.

Therefore, molecular diagnostic tests are not covered if the results will not
inform clinical decision making (for example if the patient has undergone a
recent biopsy with a definitive diagnosis or has a planned upcoming biopsy
that will be performed regardless of the result of the molecular test).
Similarly, if a molecular test is performed as a result of findings from a
pre-test, this suggests that the molecular test is informed by and performed
after the results of the pre-test are known; as such, the molecular tests
should be performed after the relevant pre-test(s).

  * IF the molecular diagnostic test is performed in-lieu of a surveillance (protocol) biopsy, the testing frequency must be no more frequent than the OPTN center-specific surveillance biopsy schedule.
  * The test demonstrates analytical validity (AV), including an analytical and clinical validation for any given measured analytes, and has demonstrated equivalence or superiority for sensitivity or specificity (depending on intended use) of detecting allograft rejection to other already-accepted tests for the same intended use measuring the same or directly comparable analytes.
  * Clinical validity (CV) of any analytes (or expression profiles) measured must be established through a study published in the peer-reviewed literature for the intended use of the test in the intended population. The degree of validity must be similar or superior to established and covered tests (see associated coverage Articles). If conducted with concordance to tissue histologic evaluation the most current Banff Classification for renal allografts or other accepted criteria (if existing) for other organs must be used.
  * The test is being used in a patient who is part of the population in which the test was analytically validated and has demonstrated CV.
  * For a given patient encounter, only one molecular test for assessing allograft status may be performed.
  * For minimally or non-invasive tests, the benefit to risk profile of the molecular test is considered by the ordering clinician to be more favorable than the benefit to risk profile of a tissue biopsy, or a tissue biopsy cannot be obtained. For example, this may be the case if a biopsy is considered medically contraindicated in a patient.
  * The test successfully completes a Molecular Diagnostic Services Program (MolDX) Technical Assessment that will ensure that AV, CV, and clinical utility criteria set in this policy are met to establish the test as Reasonable and Necessary.

Covered tests with AV that is significantly below similar services may have
coverage rescinded.

Allograft solid-organ transplantation has become a standard of care in
patients with end-stage organ disease. In some patients, these treatments,
along with other advances in care, have transformed fatal disease into
treatable and preventable disease.1-3 Transplant patients are placed on
immunosuppressant drug therapy and are routinely monitored for indicators of
rejection to prolong the survival of the donor allograft. Serologic and
laboratory markers aid in monitoring graft function and in the early detection
of AR which may occur as ACR or AMR.9 Transplant recipients may also undergo
(a) surveillance biopsies to detect histologic changes that precede functional
allograft decline and/or (b) for-cause biopsies when clinically indicated.
With early intervention, these changes may still be amenable to treatment. The
cost for managing a failed allograft may be 500% more than a patient with a
functioning transplant.4 Early detection of AR has led to significant
improvement in allograft survival in the first 12 months posttransplantation.5

The importance of graft rejection and immunosuppression was discovered early
on following the development of transplantation, a challenge that started to
be overcome with the availability of immunosuppressants, though with the
current standard-of-care for managing solid organ transplant patients,
rejection remains a common problem with a high frequency of graft failure at 5
and 10 years.4,6-8

Graft assessment is also used clinically to assist in the management of
immunosuppression; the clinical value it brings is that it allows modification
of immunosuppressive therapy so as to maximize graft longevity, which is a
focus of post-transplant care. Histology has traditionally been used, often in
conjunction with serologic and other laboratory markers as a common graft
assessment tool.8,10-15 While histology is considered the gold standard of
diagnosis at this point in time, this requires a biopsy, which is invasive and
may be associated with significant risks, complications and access to care
barriers.

Molecular diagnostic methods have emerged in an attempt to address limitations
in current diagnostics including the measurement of donor-derived cell-free
deoxyribonucleic acid (hereon cfDNA) and gene expression profile (GEP) assays,
which have been developed in a number of organ allografts including kidney,
heart, liver, and lung.16-24 The principle underlying cfDNA assays to assess
rejection is that the transplantation of a new organ involves transplantation
of new genetic material, and genetic material is shed into the bloodstream as
part of rejection.25 The fraction of cfDNA in the blood-stream may serve as a
marker of rejection.18-21 While this is a straightforward principle, DNA
concentration in the bloodstream is quite small, and therefore tests relying
on cfDNA require advanced technological methods that can accurately capture
and quantify the presence of cfDNA specific to the allograft.18,21,25 GEP
tests tend to quantify expression of numerous genes in the allograft recipient
and use these data in algorithms developed with sophisticated modeling or
machine learning to determine whether rejection is occurring.22,24,26 These
tests can not only provide information about graft status in a minimally-
invasive manner, but they can be sensitive enough to be able to detect AR
before it is evident histologically or by other clinical and laboratory
indicators.25

However, these molecular tests have different strengths and weaknesses and can
be leveraged for different populations. For example, some GEP tests have high
negative predictive value for the likelihood of AR, but may be limited in
their ability as a positive predictor for ACR or even detecting AMR, which may
still be useful in a stable patient at low risk for rejection.27 Other tests
may have higher sensitivity or positive predictive value, suitable for higher-
risk patients.18,21

While these technologies are newer, large and multicenter studies have
supported their use in renal and heart transplantation as minimally and non-
invasive methods to assess allograft status, modify immunosuppression
regimens, and avoid unnecessary biopsies.18,19,23,28-29 Evidence continues to
develop for other transplant allograft organs and other analytes.16,17,30-33
Additionally, there is evidence that while some cfDNA and GEP tests may have
different intended uses, combining both may further improve graft rejection
determination in certain circumstances.34

**Contractor Advisory Committee (CAC) Summary**

****

**Kidney and Liver Allograft CAC**

****

On November 16, 2022, Noridian and Palmetto jointly facilitated a CAC to
discuss molecular testing for the diagnosis of acute rejection in kidney or
liver transplant recipients where GEP, dd cfDNA, and multiomic tests were
discussed. The subject matter experts (SMEs) expressed a high degree of
certainty that there is sufficient evidence to support the use of molecular
tests like dd cfDNA in kidney allograft patients.

**Heart and Lung Allograft CAC**

On November 17, 2022, Noridian and Palmetto jointly facilitated a CAC to
discuss molecular testing for the diagnosis of acute rejection in heart or
lung transplant recipients where GEP and dd cfDNA tests were discussed. The
SMEs were unanimous that the evidence is sufficient to support the use of GEP
and/or dd cfDNA for surveillance of acute organ injury to help replace an
unnecessary biopsy. However, they also agreed that there is a lack of data to
support the routine use of molecular combination testing. Moreover, they did
not endorse the use of molecular diagnostic tests in lieu of biopsy in
patients with a _very_ high clinical and laboratory suspicion for acute
rejection and who can also safely tolerate a biopsy. All SMEs agreed that
these tests do not discern the etiology of organ injury, indicating that they
had a high degree of confidence in the detection of allograft injury, but
additional clinical testing was necessary to discern the cause.

Documents associated with the CAC meetings can be found here:

[Contractor Advisory Committee (CAC) - JE Part B - Noridian
(noridianmedicare.com)](https://med.noridianmedicare.com/web/jeb/policies/lcd/cac)

Numerous prior Medicare coverage decisions have considered the evidence in the
hierarchical framework of Fryback and Thornbury35 where Level 2 addresses
diagnostic accuracy, sensitivity, and specificity of the test; Level 3 focuses
on whether the information produces change in the physician's diagnostic
thinking; Level 4 concerns the effect on the patient management plan and Level
5 measures the effect of the diagnostic information on patient outcomes. To
apply this same hierarchical framework to analyze an in vitro diagnostic test,
we utilized the ACCE Model Process for Evaluating Genetic Tests.35 The
practical value of a diagnostic test can only be assessed by taking into
account subsequent health outcomes. When a proven, well established
association or pathway is available, intermediate health outcomes may also be
considered. For example, if a particular diagnostic test result can be shown
to change patient management and other evidence has demonstrated that those
patient management changes improve health outcomes, then those separate
sources of evidence may be sufficient to demonstrate positive health outcomes
from the diagnostic test.

Graft assessment is a well-accepted part of solid organ transplant management.
Evidence clearly shows that patients are living with functioning organs
transplanted from immunologically and genetic distinct individuals using
current transplant management techniques, which may demonstrate significant
heterogeneity among centers or even among individual physicians. For example,
the CAC SMEs acknowledged that only approximately 18% of transplant centers
perform routine surveillance biopsies in kidney transplant patients, because
the evidence on the benefit of that practice is conflicting. Similarly, some
centers have moved away from performing protocol biopsies in other transplant
types due to the highly invasive nature of the procedures and the high risk of
complications.

It is also well accepted within the transplant community that
immunosuppression management is an important component of post-transplant care
to both optimize graft longevity while avoiding side effects and toxicity of
immunosuppressive therapies. Graft assessment is an important decision tool
used to help clinicians optimize immunosuppressive treatment. The gold
standard for assessing rejection or injury has historically been and remains a
biopsy in conjunction with serologic criteria. However, given the invasive
nature and risks associated with a biopsy, tests that can potentially mitigate
the need for a biopsy while still providing clinicians with actionable
information that can be used to help optimize immunosuppressive therapy are
reasonable and necessary. Additionally, ongoing studies have supported that
cfDNA and GEP can accurately determine allograft status in several organ
types, and that molecular characterization can both precede and enhance
histologic findings. As such, these approaches, as a service type, are
reasonable and necessary for graft assessment.

Non-invasive graft assessment remains an actively evolving area of medicine as
does the assessment of graft rejection via histology. As such, this contractor
will continue to monitor the evidence, and new developments may impact this
coverage decision.